Aldosterone excess impairs first phase insulin secretion in primary aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2513-2520

  Fischer, Evelyn ^a   Adolf, Christian ^a   Pallauf, Anna ^a   Then, Cornelia ^a   Bidlingmaier, Martin ^a   Beuschlein, Felix ^a   Seissler, Jochen ^a,b   Reincke, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ARGININE; C PEPTIDE; GLUCOSE; INSULIN; SHORT ACTING INSULIN;

ADRENAL HYPERPLASIA; ADRENALECTOMY; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GERMANY; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION;

ADULT; ALDOSTERONE; BLOOD GLUCOSE; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84878490042     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3934     Document Type: Article

References (52)

1. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
2. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
3. Apostolopoulou K, Kunzel HE, Gerum S, et al. Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study. World J Biol Psychiatry. In press.
4. Reincke M, Meisinger C, Holle R, et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Horm Metab Res. 2010;42:435-439.
5. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. (Pubitemid 40523144)
6. Born-Frontsberg E, Reincke M, Rump LC, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab. 2009;94:1125-1130.
7. Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009;94:869-875.
8. Fallo F, Pilon C, Urbanet R. Primary aldosteronism and metabolic syndrome. Horm Metab Res. 2012;44:208-214.
9. Fallo F, Della Mea P, Sonino N, et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007;20:855-861. (Pubitemid 47176347)
10. Somloova Z, Widimsky J Jr, Rosa J, et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens. 2010; 24:625-630.
11. Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci. 2011;32:734-739.
12. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(suppl 1):S55-S60.
13. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep. 2003;5:106-109. (Pubitemid 38898939)
14. Pierluissi J, Navas FO, Ashcroft SJ. Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia. 1986;29:119-121. (Pubitemid 16162755)
15. Henquin JC. Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia. 2009;52:739-751.
16. Strauch B, Widimsky J, Sindelka G, Skrha J. Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res. 2003;52:503-506. (Pubitemid 37039916)
17. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454-459. (Pubitemid 43236909)
18. Mosso LM, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens. 2007;25:2125-2130. (Pubitemid 47476311)
19. Reincke M, Fischer E, Gerum S, et al. Observational study mortality in treated primary aldosteronism: the German Conn's Registry. Hypertension. 2012;60:618-624.
20. Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord. 2011;12:43-48.
21. Pallauf A, Schirpenbach C, Zwermann O, et al. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. Horm Metab Res. 2012;44:215-220.
22. Betz MJ, Degenhart C, Fischer E, et al. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol. 2011;165:301-306.
23. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645.
24. Ahren B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol. 2004;150:97-104. (Pubitemid 38312800)
25. Druet C, Tubiana-Rufi N, Chevenne D, Rigal O, Polak M, Levy-Marchal C. Characterization of insulin secretion and resistance in type 2 diabetes of adolescents. J Clin Endocrinol Metab. 2006;91:401-404. (Pubitemid 43236901)
26. Lansang MC, Williams GH, Carroll JS. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens. 2001;14:51-53. (Pubitemid 32105918)
27. Anzeneder L, Kircher F, Feghelm N, Fischer R, Seissler J. Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Horm Metab Res. 2011;43:355-360.
28. Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91:3457-3463. (Pubitemid 44402119)
29. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116-128. (Pubitemid 20136185)
30. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304. (Pubitemid 41242486)
31. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. (Pubitemid 41532612)
32. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428. (Pubitemid 40523737)
33. Redon J, Cifkova R, Laurent S, et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008;26:1891-1900.
34. Hannemann A, Meisinger C, Bidlingmaier M, et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol. 2011;164:751-758.
35. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-245. (Pubitemid 44309818)
36. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704-711.
37. Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984-992. (Pubitemid 47329563)
38. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007;30:2349-2354. (Pubitemid 47359046)
39. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab. 2010;95:1986-1990.
40. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88-90. (Pubitemid 351442920)
41. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88:2399-2403. (Pubitemid 36724403)
42. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957. (Pubitemid 26114161)
43. Ranade K, Wu KD, Risch N, et al. Genetic variation in aldosterone synthase predicts plasma glucose levels. Proc Natl Acad Sci USA. 2001;98:13219-13224. (Pubitemid 33051343)
44. Luther JM, Luo P, Kreger MT, et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia. 2011;54:2152-2163.
45. Shamiss A, Carroll J, Rosenthal T. Insulin resistance in secondary hypertension. Am J Hypertens. 1992;5:26-28.
46. Shimamoto K, Shiiki M, Ise T, et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens. 1994;8:755-759. (Pubitemid 24319387)
47. Haluzik M, Sindelka G, Widimsky J Jr, Prazny M, Zelinka T, Skrha J. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens. 2002;16:41-45. (Pubitemid 34134092)
48. Sindelka G, Widimsky J, Haas T, Prazny M, Hilgertova J, Skrha J. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes. 2000;108:21-25. (Pubitemid 30160431)
49. Widimsky J Jr, Sindelka G, Haas T, Prazny M, Hilgertova J, Skrha J. Impaired insulin action in primary hyperaldosteronism. Physiol Res. 2000;49:241-244. (Pubitemid 30365884)
50. Skrha J, Haas T, Sindelka G, et al. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab. 2004;89:135-141. (Pubitemid 38183872)
51. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000;49:1751-1760.
52. Giacchetti G, Ronconi V, Turchi F, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007;25:177-186. (Pubitemid 44885680)